Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Apr 30 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal · 6% above its 52-week low
| 2.88 | 52-week high | +2909.40% |
| 0.3500 | Previous month high | +265.73% |
| 0.1650 | Previous week high | +72.41% |
| 0.1520 | Previous month low | +58.83% |
| 0.1380 | Previous week low | +44.20% |
| 0.1363 | R3 (classic) | +42.46% |
| 0.1257 | R2 (classic) | +31.31% |
| 0.1150 | Previous day high | +20.17% |
| 0.1113 | R1 (classic) | +16.34% |
| 0.1007 | Pivot | +5.19% |
| 0.0957 | Price now | |
| 0.0900 | Previous day low | −5.96% |
| 0.0900 | 52-week low | −5.96% |
| 0.0863 | S1 (classic) | −9.79% |
| 0.0757 | S2 (classic) | −20.93% |
| 0.0613 | S3 (classic) | −35.91% |
None of the 29 investors followed here reported a position in SNTI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SNTI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.8 | -5.6 | -14.0 | 13.9 | 2.9 | 15.5 | -69.0 | 10.9 | -17.5 | -47.1 | -42.0 | −90.8% | |
| 2025 | 24.2 | -31.0 | 11.6 | -1.2 | -5.4 | -32.8 | -19.4 | -13.5 | -4.1 | 44.0 | 9.9 | -53.4 | −70.4% |
| 2024 | -31.8 | -4.4 | -12.3 | -4.5 | -16.7 | -8.0 | -16.3 | 14.7 | -14.7 | -4.0 | -0.5 | 62.5 | −46.8% |
| 2023 | 30.0 | -18.2 | -21.3 | -16.9 | -9.8 | -29.1 | 37.5 | -24.6 | -36.5 | -32.2 | 53.6 | 53.5 | −53.2% |
| 2022 | 0.4 | 0.6 | -0.9 | 0.3 | 0.4 | -80.2 | 59.3 | -37.4 | 10.7 | 6.9 | -0.9 | -38.7 | −85.7% |
| 2021 | -0.6 | -1.0 | 0.8 | 0.2 | 1.5 | -2.1 | -0.2 | −1.4% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 9, 2025 | New Enterprise Associates 15, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 3.33M | — |
| Mar 9, 2025 | Rajangam KanyaPresident | Conversion of Exercise of derivative security at price 2.25 per share. | 33K | $74.25K |
| Mar 9, 2025 | Bayer Healthcare L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 2.22M | — |
| Mar 9, 2025 | Celadon Partners Spv 24Beneficial Owner of more than 10% of a Class of Security | — | 9.78M | — |
| Mar 6, 2025 | Rajangam KanyaPresident | — | 78.4K | — |
| Mar 6, 2025 | Lu Timothy K M.D., Ph.D.Chief Executive Officer | — | 642.4K | — |
| Feb 5, 2025 | Rajangam KanyaPresident | Sale at price 4.07 - 4.37 per share. | 1.5K | $6.07K |
| Feb 5, 2025 | Lu Timothy K M.D., Ph.D.Chief Executive Officer | Sale at price 4.07 - 4.36 per share. | 4.5K | $18.34K |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.